Literature DB >> 25869390

BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Cathy Bennett1, Paul Moayyedi2, Douglas A Corley3, John DeCaestecker4, Yngve Falck-Ytter5, Gary Falk6, Nimish Vakil7, Scott Sanders8, Michael Vieth9, John Inadomi10, David Aldulaimi11, Khek-Yu Ho12, Robert Odze13, Stephen J Meltzer14, Eamonn Quigley15, Stuart Gittens16, Peter Watson17, Giovanni Zaninotto18, Prasad G Iyer19, Leo Alexandre20, Yeng Ang21, James Callaghan22, Rebecca Harrison4, Rajvinder Singh23, Pradeep Bhandari24, Raf Bisschops25, Bita Geramizadeh26, Philip Kaye27, Sheila Krishnadath28, M Brian Fennerty29, Hendrik Manner30, Katie S Nason31, Oliver Pech32, Vani Konda33, Krish Ragunath34, Imdadur Rahman35, Yvonne Romero19, Richard Sampliner36, Peter D Siersema37, Jan Tack38, Tony C K Tham39, Nigel Trudgill40, David S Weinberg41, Jean Wang42, Kenneth Wang19, Jennie Y Y Wong43, Stephen Attwood44, Peter Malfertheiner45, David MacDonald46, Hugh Barr47, Mark K Ferguson48, Janusz Jankowski49.   

Abstract

OBJECTIVES: Barrett's esophagus (BE) is a common premalignant lesion for which surveillance is recommended. This strategy is limited by considerable variations in clinical practice. We conducted an international, multidisciplinary, systematic search and evidence-based review of BE and provided consensus recommendations for clinical use in patients with nondysplastic, indefinite, and low-grade dysplasia (LGD).
METHODS: We defined the scope, proposed statements, and searched electronic databases, yielding 20,558 publications that were screened, selected online, and formed the evidence base. We used a Delphi consensus process, with an 80% agreement threshold, using GRADE (Grading of Recommendations Assessment, Development and Evaluation) to categorize the quality of evidence and strength of recommendations.
RESULTS: In total, 80% of respondents agreed with 55 of 127 statements in the final voting rounds. Population endoscopic screening is not recommended and screening should target only very high-risk cases of males aged over 60 years with chronic uncontrolled reflux. A new international definition of BE was agreed upon. For any degree of dysplasia, at least two specialist gastrointestinal (GI) pathologists are required. Risk factors for cancer include male gender, length of BE, and central obesity. Endoscopic resection should be used for visible, nodular areas. Surveillance is not recommended for <5 years of life expectancy. Management strategies for indefinite dysplasia (IND) and LGD were identified, including a de-escalation strategy for lower-risk patients and escalation to intervention with follow-up for higher-risk patients.
CONCLUSIONS: In this uniquely large consensus process in gastroenterology, we made key clinical recommendations for the escalation/de-escalation of BE in clinical practice. We made strong recommendations for the prioritization of future research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25869390      PMCID: PMC4436697          DOI: 10.1038/ajg.2015.55

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  175 in total

1.  Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Joaquín Molina; Juan Bermejo; Manuel Canteras
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

Review 2.  The Delphi technique: myths and realities.

Authors:  Catherine Powell
Journal:  J Adv Nurs       Date:  2003-02       Impact factor: 3.187

3.  Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.

Authors:  Richard R Gurski; Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester; Cedric G Bremner; Parakrama T Chandrasoma; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2003-05       Impact factor: 6.113

4.  Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.

Authors:  F Kastelein; S van Olphen; E W Steyerberg; M Sikkema; M C W Spaander; C W N Looman; E J Kuipers; P D Siersema; M J Bruno; E W de Bekker-Grob
Journal:  Gut       Date:  2014-07-18       Impact factor: 23.059

5.  Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus.

Authors:  C Ell; A May; L Gossner; O Pech; E Günter; G Mayer; R Henrich; M Vieth; H Müller; G Seitz; M Stolte
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

6.  Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus.

Authors:  R C Fitzgerald; I T Saeed; D Khoo; M J Farthing; W R Burnham
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

7.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study.

Authors:  Douglas A Corley; Theodore R Levin; Laurel A Habel; Noel S Weiss; Patricia A Buffler
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

8.  Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.

Authors:  Thomas L Vaughan; Alan R Kristal; Patricia L Blount; Douglas S Levine; Patricia C Galipeau; Laura J Prevo; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-08       Impact factor: 4.254

9.  Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation.

Authors:  Nicole Carlson; Juan Lechago; Joel Richter; Richard E Sampliner; Leif Peterson; Regina M Santella; John R Goldblum; Gary W Falk; Atilla Ertan; Mamoun Younes
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

10.  Yield of intestinal metaplasia in patients with suspected short-segment Barrett's esophagus (SSBE) on repeat endoscopy.

Authors:  Thomas F Jones; Prateek Sharma; Bisher Daaboul; Rachel Cherian; M Mayo; Margarita Topalovski; Allan P Weston
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

View more
  39 in total

Review 1.  Endoluminal therapies for Barrett's esophagus.

Authors:  Carmen L Mueller; Lorenzo E Ferri
Journal:  Obes Surg       Date:  2016-04       Impact factor: 4.129

Review 2.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

3.  Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.

Authors:  Angelique Levert-Mignon; Michael J Bourke; Sarah J Lord; Andrew C Taylor; Antony R Wettstein; Melanie Edwards; Natalia K Botelho; Rebecca Sonson; Chatura Jayasekera; Oliver M Fisher; Melissa L Thomas; Finlay Macrae; Damian J Hussey; David I Watson; Reginald V Lord
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

Review 4.  Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.

Authors:  Stéphane Groulx; Heather Limburg; Marion Doull; Scott Klarenbach; Harminder Singh; Brenda J Wilson; Brett Thombs
Journal:  CMAJ       Date:  2020-07-06       Impact factor: 8.262

Review 5.  Endoscopic modalities for the diagnosis of Barrett's oesophagus.

Authors:  Neel Sharma; Supriya Srivastava; Florian Kern; Wa Xian; Teh Ming; Frank McKeon; Khek Yu Ho
Journal:  United European Gastroenterol J       Date:  2015-12-15       Impact factor: 4.623

6.  Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control.

Authors:  Srinadh Komanduri; Peter J Kahrilas; Kumar Krishnan; Tim McGorisk; Kiran Bidari; David Grande; Laurie Keefer; John Pandolfino
Journal:  Am J Gastroenterol       Date:  2017-02-14       Impact factor: 10.864

Review 7.  Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative.

Authors:  Raf Bisschops; Miguel Areia; Emmanuel Coron; Daniela Dobru; Bernd Kaskas; Roman Kuvaev; Oliver Pech; Krish Ragunath; Bas Weusten; Pietro Familiari; Dirk Domagk; Roland Valori; Michal F Kaminski; Cristiano Spada; Michael Bretthauer; Cathy Bennett; Carlo Senore; Mário Dinis-Ribeiro; Matthew D Rutter
Journal:  United European Gastroenterol J       Date:  2016-08-21       Impact factor: 4.623

Review 8.  Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.

Authors:  Sachin Wani; V Raman Muthusamy; Nicholas J Shaheen; Rena Yadlapati; Robert Wilson; Julian A Abrams; Jacques Bergman; Amitabh Chak; Kenneth Chang; Ananya Das; John Dumot; Steven A Edmundowicz; Glenn Eisen; Gary W Falk; M Brian Fennerty; Lauren Gerson; Gregory G Ginsberg; David Grande; Matt Hall; Ben Harnke; John Inadomi; Janusz Jankowski; Charles J Lightdale; Jitin Makker; Robert D Odze; Oliver Pech; Richard E Sampliner; Stuart Spechler; George Triadafilopoulos; Michael B Wallace; Kenneth Wang; Irving Waxman; Srinadh Komanduri
Journal:  Am J Gastroenterol       Date:  2017-06-01       Impact factor: 10.864

9.  Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.

Authors:  M Ma; S Shroff; M Feldman; M DeMarshall; C Price; A Tierney; G W Falk
Journal:  Dis Esophagus       Date:  2017-03-01       Impact factor: 3.429

Review 10.  Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus.

Authors:  Spyridon Michopoulos
Journal:  Ann Transl Med       Date:  2018-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.